Key Stats for Boston Scientific Stock
- This Week Performance: 1.3%
- 52-Week Range: $73 to $110
- Current Price: $76
What Happened to Boston Scientific Stock?
Boston Scientific (BSX) stock trades at $76, sitting close to their 52-week low of $72.69 and roughly 31% below their 52-week high of $109.50, after the stock suffered its steepest single-day drop in over 25 years on February 5.
The selloff was triggered by Q4 EP sales of $890 million missing the Street’s $933 million estimate, while WATCHMAN grew a strong 29% but came in just below consensus, prompting J.P. Morgan to warn that investors now have reason to question the trajectory of both key growth drivers.
The broader Q4 results were actually solid, with revenue of $5.29 billion and adjusted EPS of $0.80 both beating estimates, full year organic growth hitting 15.8%, and free cash flow surging 38% to $3.66 billion, but the market focused entirely on the two misses.
Wall Street is now wrestling with a perception shift, moving from viewing Boston Scientific as a high-growth PFA and WATCHMAN compounder to questioning whether both businesses are decelerating faster than expected as competitors enter and capacity constraints limit market expansion.
More than a dozen analysts slashed price targets on February 5, with Deutsche Bank cutting to $90, Leerink to $95, Wells Fargo to $94, and Truist to $95, reflecting a broad reset of expectations even as most maintained Buy ratings on the stock.
The CHAMPION trial readout at ACC on March 28 now becomes the most critical near-term catalyst, with a positive result potentially expanding WATCHMAN’s addressable patient pool from 5 million to 20 million globally and forcing the market to reassess the entire growth trajectory.
Where is the BSX Stock Headed?
Despite the brutal post-earnings selloff, the CHAMPION trial readout at ACC on March 28 and the eventual Penumbra close give Boston Scientific two near-term events that could fundamentally reframe the growth story and force a reassessment of the current $76 price.
The fundamental case remains compelling, with Street estimates projecting 2026 revenue of $22.28 billion (+11% YoY) and normalized EPS of $3.46 (+13.2%), while EBIT margins expand to 28.5% as the company continues its multi-year track record of consistent operational leverage.
Wall Street stands firmly behind the stock even after the selloff, with 25 Buys and 9 Outperforms among 35 analysts as of February 19, and a mean price target of $104.75 implying roughly 38% upside from the current price of $76.
The target spread runs from a low of $83 to a high of $124, a range that captures the full debate between bears who see EP and WATCHMAN structurally slowing and bulls who believe the CHAMPION trial and Penumbra can reignite the premium growth multiple.
TIKR’s advanced valuation model built on the same earnings trajectory that drove BSX’s 10-year revenue CAGR of 10.4% prices the stock at $127.81 by December 2030, implying a 68.8% total return and an 11.4% annualized IRR from current levels, suggesting the post-earnings selloff has created a significant gap between price and intrinsic value.
The primary risk is P/E multiple compression, with the model assuming a 5.3% annual P/E contraction, meaning Boston Scientific must sustain nearly 11% EPS growth just to offset de-rating, a tough ask if the CHAMPION trial disappoints or EP share losses accelerate beyond what management has guided.
At $76, Boston Scientific looks meaningfully undervalued relative to its fundamentals, analyst consensus, and long-term model, but it is a conviction call that requires patience through the CHAMPION readout and confidence that the EP slowdown is cyclical rather than structural.
Value Any Stock in Under 60 Seconds (It’s Free)
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
